Humira Sales Data

Rank 3 Current sales rank, all
U.S. Pharmaceuticals.

Last updated: February 2014 (updated quarterly).
The following data shows Humira U.S. retail sales in Q4 2013 compared to previous quarters.

Date Range Sales Rank Sales ($000) Units (000)
Q4 2013 3 3.86% 1.52%
Q3 2013 3 4.90% -4.91%
Q2 2013 3 (3) 10.22% 9.83%
Q1 2013 6 (1) 0.91% -5.68%
Q4 2012 5 4.70% 4.53%
Q3 2012 5 (2) 13.45% 7.56%
Q2 2012 7 (3) 9.43% 8.97%
Q1 2012 10 2.50% -2.85%
Q4 2011 10 (1) 3.18% 2.55%
Q3 2011 11 (3) 3.95% 3.01%
Q2 2011 14 6.32% 2.31%
Q1 2011 14

* Units refer to the number of packages sold.

Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.

Related News

DateArticle
October 1, 2012Abbott Labs Gets New Approval for Its Drug Humira
August 23, 2011Injectable Psoriasis Drugs May Not Hike Heart Risks: Study
April 12, 2011Clues to Why Rheumatoid Arthritis Drug Humira Fails Some Patients
September 4, 2008FDA Demands Tougher Warnings on Immunosuppressive Drugs
June 4, 2008Amgen and Wyeth Statement on the FDA Early Communication About Tumor Necrosis Factor (TNF) Blockers
June 4, 2008Early Communication About an Ongoing Safety Review of Tumor Necrosis Factor (TNF) Blockers (marketed as Remicade, Enbrel, Humira, and Cimzia)
Hide
(web3)